We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Vaccine Manufacture and Supply – News and Features

News

Valneva Announces Approval of an EB66®-based Prototype Influenza Vaccine in Japan

The vaccine was developed by the Chemo-Sero Therapeutic Research Institute (Kaketsuken) in collaboration with GlaxoSmithKline using Valneva’s EB66® cell line.
News

Valneva Announces Signing of an Exclusive License Agreement

Agreement on EB66® cell line for human and veterinary vaccines in People’s Republic of China.
News

Adapting Influenza for Vaccine Mass Production

The ability to grow influenza in cell culture rather than chicken eggs paves the way for mass production of the vaccine.
News

FUJIFILM Completes Acquisition of Kalon Biotherapeutics

Acquisition enhances Texas’ growing reputation as a global biotechnology leader.
News

Johnson & Johnson Announces Major Commitment of Up to $200 Million

Commitment to speed Ebola vaccine development and significantly expand production.
News

Johnson & Johnson to Speed Ebola Vaccine Development, Significantly Expand Production

Company has committed up to $200M to vaccine program in development at its Janssen Pharmaceutical Companies.
News

Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of ALL Patients Studied

University of Pennsylvania and Children's Hospital of Philadelphia studies reveal unprecedented results with investigational therapy made from patients' own immune cells.
News

InfinityQS Demonstrates Quality’s Impact on the Vaccine Manufacturing Chain in New eBook

“Transforming the Vaccine Manufacturing Chain,” highlights how pharmaceutical companies can ensure quality and accelerate time to market with Manufacturing Intelligence technology.
News

NIH Awards Seven New Vaccine Adjuvant Discovery Contracts

Total funding for these contracts reach approximately $70 million over five years.
News

Calixar and VirPath Develop an Innovative Manufacturing Process

A new antigens formulation against pandemic flu (A H1N1 virus) proved six times more effective than other vaccines.
Advertisement